Dublin, June 17, 2021 (GLOBE NEWSWIRE) -- The "Global Veterinary Oncology Market (2020-2025) by Type, Animal Type, Therapy Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.
The Global Veterinary Oncology Market is estimated to be USD 60.44 Mn in 2020 and is expected to reach USD 86.75 Mn by 2025, growing at a CAGR of 7.5%.
The key factors driving the growth of this market include upsurge in the prevalence of cancer in pets, increasing research and investments in pet cancer, growing focus on animal safety whereas high cost associated with chemotherapies, immunotherapies, and targeted therapies are major factors restraining the veterinary oncology market growth.
Market Segmentation
The Global Veterinary Oncology Market is segmented further based on Type, Animal Type, Therapy and Geography.
By Type, the market is classified into Lymphoma, mast cell cancer, mammary and squamous cell cancer, others like anal sac carcinoma. Rising incidence of mast cell cancer in dogs is further expected to drive the market growth.
By Animal Type, the market is classified into Companion Animal or Livestock Animal.
By Therapy, the market is classified into Chemotherapy, Combination Therapy, Immunotherapy and Targeted Therapy. Chemotherapy has progressed dramatically with canine oncology.
By Geography, North America is projected to dominate the market over the forecast period.
Recent Developments
1. Boehringer Ingelheim took over AMAL Therapeutics, a biotechnology company focused on cancer immunotherapy. The acquisition helped the company to become an innovator of novel cancer therapies, including immuno-oncology treatments. July 2019.
2. Elanco acquired Aratana Therapeutics in April 2019, after which, the company declared the formation of a commercial team devoted to the veterinary specialty business.
3. Another contribution by the market player in August 2019, was the initiation of Phase 2 clinical trial by PharmAust in Australia with its leading veterinary drug candidate, monepantel, to treat canine cancer.
Company Profiles
Some of the companies covered in this report are Boehringer Ingelheim International GmbH, Karyopharm Therapeutics, Inc., Regeneus Ltd., Elanco Animal Health, Inc., Zoetis, Inc., Varian Medical Systems, Inc., PetCure Oncology, LLC (Accelitech, LLC), AB Science SA, Rhizen Pharmaceuticals S.A., and Nippon Zenyaku Kogyo Co., Ltd., etc.
Competitive Quadrant
The report includes a Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.
Why buy this report?
- The report offers a comprehensive evaluation of the Global Veterinary Oncology Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
- The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
- The report includes in-depth market analysis using Porter's 5 force model and the Ansoff Matrix. The impact of Covid-19 on the market is also featured in the report.
- The report also contains the competitive analysis using the Competitive Quadrant, the analyst's proprietary competitive positioning tool.
Report Highlights:
- A complete analysis of the market, including parent industry
- Important market dynamics and trends
- Market segmentation
- Historical, current, and projected size of the market based on value and volume
- Market shares and strategies of key players
- Recommendations to companies for strengthening their foothold in the market
Key Topics Covered:
1 Report Description
2 Research Methodology
3 Executive Summary
4 Market Overview
4.1 Introduction
4.2 Market Dynamics
4.2.1 Drivers
4.2.1.1 Upsurge in the prevalence of cancer in pets
4.2.1.2 Increasing research and investments in pet cancer
4.2.1.3 Growing focus on animal safety
4.2.2 Restraints
4.2.2.1 High cost of pet cancer treatment
4.2.2.2 Lack of awareness among pet owners about pet disease
4.2.2.3 Adverse effects of drugs used for pet cancer treatment
4.2.3 Opportunities
4.2.3.1 Surge in Awareness Related to Animal Healthcare
4.2.4 Challenges
4.2.4.1 Lack of Standardization in Veterinary Cross
4.3 Trends
5 Market Analysis
5.1 Porter's Five Forces Analysis
5.2 Impact of COVID-19
5.3 Ansoff Matrix Analysis
6 Global Veterinary Oncology Market segment, By Type
6.1 Lymphoma
6.2 Mast Cell Cancer
6.3 Mammary and Squamous Cell Cancer
6.4 Others (Anal Sac Carcinoma)
7 Global Veterinary Oncology Market segment, By Animal
7.1 Companion Animal
7.2 Livestock Animal
8 Global Veterinary Oncology Market segment, By Therapy
8.1 Chemotherapy
8.2 Combination Therapy
8.3 Immunotherapy
8.4 Targeted Therapy
9 Global Veterinary Oncology segment Market, By Geography
9.1 Introduction
9.2 North America
9.2.1 US
9.2.2 Canada
9.2.3 Mexico
9.3 South America
9.3.1 Brazil
9.3.2 Argentina
9.4 Europe
9.4.1 UK
9.4.2 France
9.4.3 Germany
9.4.4 Italy
9.4.5 Spain
9.4.6 Rest of Europe
9.5 Asia-Pacific
9.5.1 China
9.5.2 Japan
9.5.3 India
9.5.4 Indonesia
9.5.5 Malaysia
9.5.6 South Korea
9.5.7 Australia
9.5.8 Russia
9.5.9 Rest of APAC
9.6 Rest of the World
9.6.1 Qatar
9.6.2 Saudi Arabia
9.6.3 South Africa
9.6.4 United Arab Emirates
9.6.5 Latin America
10 Competitive Landscape
10.1 Competitive Quadrant
10.2 Market Share Analysis
10.3 Competitive Scenario
10.3.1 Mergers & Acquisitions
10.3.2 Agreement, Collaborations, & Partnerships
10.3.3 New Product Launches & Enhancements
10.3.4 Investments & Funding
11 Company Profiles
11.1 Boehringer Ingelheim International GmbH
11.2 Elanco
11.3 Zoetis
11.4 PetCure Oncology
11.5 Accuray Incorporated
11.6 Varian Medical System, Inc.
11.7 Nippon Zenyaku Kogyo Co., Ltd.
11.8 Morphogenesis, Inc.
11.9 Karyopharm Therapeutics, Inc.,
11.10 Regeneus Ltd.
11.11 One Health
11.12 Zenoaq
11.13 VetDC
11.14 AdvaVet, Inc.
11.15 Rhizen Pharmaceutical SA.
12 Appendix
For more information about this report visit https://www.researchandmarkets.com/r/9buafh